Fennec Pharmaceuticals Aktie

Fennec Pharmaceuticals reported record net product sales of $44.6 million for 2025 and $13.8 million in Q4, driven by expanded commercial reach and growth in the AYA and community oncology markets. Its Fennec HEARS patient‑support program hit all‑time highs with conversion rates improving from 50% to 70% in 2025. The company ended 2025 with $36.8 million cash and zero debt after a $21.8 million paydown, expects positive cash flow in Q1 2026, but plans to raise cash operating expenses to about $50 million in 2026 to fund commercial and medical expansion. Management also announced a U.S. patent settlement that prevents Cipla from entering the market with a generic sodium thiosulfate until September 1, 2033. » Więcej na finance.yahoo.com

Fennec Pharmaceuticals reported Q4 2025 EPS of -0.17 USD (forecast 0.03 USD) and revenue of 13.77 million USD (expectation 14.56 million USD). The stock fell about 17.45% in premarket trading. For 2025 the company shows a full-year revenue increase of 50% thanks to strong PEDMARK sales and is debt-free, but expects operating costs to rise 43% in 2026. Management emphasizes the commercial momentum of PEDMARK and plans investments in sales and medical, but sees short-term profitability risks. » Więcej na de.investing.com

The cancer institute at Tampa General Hospital is launching a study to evaluate Fennec’s sodium thiosulfate injection PEDMARK in adolescent, young adult and adult patients receiving cisplatin chemotherapy, including audiological monitoring and real-world data. PEDMARK is approved in the US for pediatric patients, received FDA approval in 2022 and European Commission approval in 2023; the drug has orphan status in the US and patent protection until 2039. Fennec has an exclusive licensing agreement with Norgine for Europe, the UK, Australia and New Zealand, recently recorded a strong share-price increase and shows high gross margins despite being in an early commercial phase. » Więcej na de.investing.com